Early phase clinical trial units (epctu)

Active Awarded Last action

Contract number
75N93022D00017
Awardee
Awarding agency
Task orders
2 $3,697,312 obligated

Award facts

Opportunity
Combined order value
  • $3,697,312 Current, with exercised options
  • $4,651,213 Potential, with all options
Last date to order 48% complete
IDV ceiling 1% used
$346,610,277.00
Award type
Multiple award
Who can order
Only the awarding agency
Set-aside
No set-aside
Competition
Full and Open Competition · 6 offers Negotiated Proposal / Quote
Pricing
Cost Plus Fixed Fee
Legislative mandates

Award details come from SAM.gov/FPDS.

About this IDV

The National Institute of Allergy and Infectious Diseases awarded an indefinite-delivery contract to PPD Development LP on January 14, 2022, with a ceiling of $346.6 million and ultimate completion date of January 13, 2032. This is a multiple-award vehicle with no set-aside designation. Place of performance is Cape Fear, North Carolina, with domestic and international scope for clinical trial execution.

The EPCTU contract supports Phase 0 through Phase III clinical trials of investigational infectious disease products, including proof-of-concept studies in healthy and diseased populations and bioanalysis services as needed. NAICS codes are 541715 and 541712; PSC codes are R425 and R499.

Two delivery orders have been issued under this IDIQ. The base award task order (75N93022F00001), issued January 14, 2022, carries a ceiling of $1.86 million and covers administration, overall clinical operations support, and concept development through January 13, 2032. A second delivery order, awarded June 29, 2023, carries a ceiling of $2.79 million and requires PPD to execute Phase 0 through Phase II trials with completion by January 31, 2026; this order uses cost-plus-fixed-fee pricing.

Task orders

Task order Ordering agency Obligated Awarded
Epctu 75N93023F00001 National Institute of Allergy and Infectious Diseases (NIH) $2,791,811
Task order 75N93022F00001 base award National Institute of Allergy and Infectious Diseases (NIH) $905,501

Transactions

Action Obligated Date
Other Administrative Action P00007 · EO 14398 - early phase clinical trial units (epctu) $0
Supplemental Agreement for work within scope P00006 $0
Supplemental Agreement for work within scope P00005 $0
Supplemental Agreement for work within scope P00004 $0
Other Administrative Action P00003 $0
Supplemental Agreement for work within scope P00002 $0
Other Administrative Action P00001 $0
Original award $0

Quick answers

Who was awarded contract 75N93022D00017?

75N93022D00017 was awarded to PPD Development LP by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on January 14, 2022.

How much is contract 75N93022D00017 worth?

Orders under 75N93022D00017 have obligated $3,697,312. Their combined potential value, with all options, is $4,651,213. 75N93022D00017's own ceiling is $346,610,277.

How many orders have been placed under contract 75N93022D00017?

2 orders have been placed under 75N93022D00017, the latest on June 29, 2023.

Who can order from contract 75N93022D00017?

75N93022D00017 is a multiple award indefinite delivery contract. Only the awarding agency can place orders on it.

Is contract 75N93022D00017 part of a contract vehicle?

Yes. 75N93022D00017 is part of Early Phase Clinical Trial Units (EPCTU).

Was contract 75N93022D00017 competed?

The extent of competition for 75N93022D00017 was full and open competition. The government received 6 offers.

On GovTribe

See this IDV's full record

  • Every order and transaction
  • The awardee's other awards and teaming partners
  • Similar IDVs and recompete opportunities
  • Ask GovTribe AI about this IDV